Press Release: Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia(R) over 2.5 years

-- Phase III ALIGN study results showed reduced rate of kidney function decline by 34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1 -- Vanrafia reduced protein in urine by 38.3% vs placebo at 9 m...

www.finanzen.ch

Zum Originalartikel